Compare CPIX & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPIX | MCHX |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.6M | 66.3M |
| IPO Year | 2007 | 2003 |
| Metric | CPIX | MCHX |
|---|---|---|
| Price | $3.18 | $1.51 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 95.4K | 12.0K |
| Earning Date | 03-03-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.70 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $42,010,949.00 | ★ $90,291,000.00 |
| Revenue This Year | N/A | $9.12 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.75 | N/A |
| 52 Week Low | $1.85 | $1.26 |
| 52 Week High | $6.27 | $2.30 |
| Indicator | CPIX | MCHX |
|---|---|---|
| Relative Strength Index (RSI) | 46.32 | 57.39 |
| Support Level | $2.95 | $1.35 |
| Resistance Level | $3.69 | $1.60 |
| Average True Range (ATR) | 0.23 | 0.09 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 75.00 | 85.79 |
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.